Latest News and Press Releases
Want to stay updated on the latest news?
-
Medicovestor wins First Place at the 2025 Next Star Biomedical Competition in Boston for groundbreaking ADC platforms targeting pancreatic & ovarian cancer
-
FDA grants Orphan Drug Designation to Medicovestor’s ADoBind MC001, a novel ADC targeting hard-to-treat pancreatic cancer.
-
Medicovestor and Sanyou team up to develop first-in-class chemoimmunotherapy ADCs, combining AI antibody tech with novel dual-targeting platforms.